Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): A 10 year experience

Clinical Research in Cardiology

Volumn 97, Issue 4, 2008, Pages 234-243

  Kuhn, Horst ^a   Lawrenz, Thorsten ^a   Lieder, Frank ^a   Leuner, Christian ^a   Strunk Mueller, Claudia ^a   Obergassel, Ludger ^a   Bartelsmeier, Markus ^a   Stellbrink, Christoph ^a  

^a OWL University   (Germany)

Author keywords

Alcohol septal ablation; Hypertrophic cardiomyopathy; Percutaneous intervention; TASH

Indexed keywords

ALCOHOL;

ADULT; AGED; ARTICLE; CATHETER ABLATION; CAUSE OF DEATH; FEMALE; HEART SURGERY; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PROPORTIONAL HAZARDS MODEL; SUDDEN DEATH; SURGICAL MORTALITY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; FEMALE; HEART SEPTUM; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; SOLVENTS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 41549132685     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0616-7     Document Type: Article

References (36)

1. Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G (2001) Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:846-853
2. Braunwald E (1997) A new treatment for hypertrophic cardiomyopathy? Eur Heart J 18:709-710
3. Cheng To (2004) In percutaneous septal myocardial ablation for hypertrophic obstructive cardiomyopathy, it is not the speed of intracoronary alcohol injection but the amount of alcohol injected that determines the resulting infarct size. Circulation 110:23
4. Coats AJ, Henein M, Rather M, Sigwart U, Seggewiss H, Wang D, Yousufuddin M, Shamim W (2003) Retraction: Shamim et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med 347:1326-1333
5. Elliott P, Gimeno JR, Tome MT, Shah J, Ward D, Thamann R, Mogensen J, McKenna WJ (2006) Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 27:1933-1941
6. Faber L, Meissner A, Ziemssen P, Seggewiss H (2000) Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 83:326-331
7. Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer WH (2005) A prospective follow up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy-the Baylor experience (1996-2002). Clin Cardiol 28:124-130
8. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Müller C, Kuhn H (2002) Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, NYHA functional class III or IV and outflow obstruction only under provocable conditions. Circulation 106:454-459
9. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Müller C, Kuhn H (1999) Acute and long-term results after transcoronary ablation of septum hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342-1354
10. Keng FYJ, Chang SM, Cwajg E, He Z, Lakkis NM, Nagueh SF, Spencer WH, Verani MS (2002) Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation. J Nucl Cardiol 9:594-600
11. Klues HG, Leuner C, Kuhn H (1992) Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopthy: increase in gradient after exercise. J Am Coll Cardiol 19:527-533
12. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Hurrington D, Fassbender D, Gleichmann U, Sigwart U (1997) Non-surgical septum reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 95:2075-2081
13. Kuhn H, Gietzen F, Leuner Ch, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new catheter-based concept of treatment. Eur Heart J 18:846-851
14. Kuhn H, Gietzen FH, Leuner CH, Schäfers M, Schober O, Strunk-Müller C, Obergassel L, Freick M, Gockel B, Lieder F, Raute-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(4):41-54
15. Kuhn H, Gietzen F, Mercier J, Lösse B, Köhler E, Schulte HD, Bircks W, Loogen F (1983) Studies of the clinical picture, course, and prognosis of different forms of hypertrophic cardiomyopathy. Z Kardiol 72:83-98
16. Kuhn H, Gietzen F, Schäfers M, Freick M, Gockel B, Strunk-Müller C, Jachmann E, Schober O (1999) Changes of left ventricular outflow tract after transcoronary ablation of septum hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transesophageal echocardiography and measuring of myocardial glucose utilization and perfusion. Eur Heart J 20:1808-1817
17. Kuhn H, Lawrenz T, Lieder F, Gietzen FH, Obergassel L, Strunk-Mueller C, Stolle B, Leuner C (2004) Alcohol septal ablation in the treatment of hypertrophic obstructive cardiomyopathy: a seven-year experience. In: Maron B (ed) Diagnosis and management of hypertrophic cardiomyopathy, Blackwell Futura, Malden, Massachusetts pp 279-296
18. Kuhn H, Seggewiss, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L (2004) Catheter based therapy for hypertrophic obstructive cardiomyopathy: first in hospital outcome analysis of the German TASH-Registry. Z Kardiol 94:23-31
19. Lawrenz T, Lieder F, Bartelsmeier M, Leuner C, Borchert B, Meyer zu Vilsendorf D, Strunk-Mueller C, Reinhardt J, Feuchtl A, Stellbrink C, Kuhn H (2007) Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiologic investigation in 172 patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 49:2356-2363
20. Lawrenz T, Lieder F, Leuner C, Obergassel L, Gockel B, Strunk-Mueller C, Kuhn H (2003) What is the correct amount of ethanol in the catheter based treatment for hypertrophic obstructive cardiomyopathy? Eur Heart J 24, abstr. Suppl:136
21. Lawrenz T, Obergassel L, Lieder F, Leuner C, Strunk-Mueller C, Meyer zu Vilsendorf D, Beer G, Kuhn H (2005) Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pace 28:1-6
22. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED (2003) ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687-1713
23. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. New Engl J Med 348:295-303
24. Obergassel L, Lawrenz T, Gietzen FH, Lieder F, Leuner, Kuhn H, Stellbrink C (2006) Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation. Clin Res Cardiol 95:254-260
25. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocci S, Gersh BJ, Ackermann MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA (2005) Long term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46:470-476
26. Ralph-Edwards A, Woo A, McCrindle BW, Shapero IL, Schwartz L, Rakowski H, Wigle ED, Williams WG (2005) Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 129:351-358
27. Raute-Kreinsen U (2003) Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy. Pathol Res Pract 199:121-127
28. Reith S, Klues HG (2003) Therapie und Risikostratefizierung der Hypertrophen Kardiomyopathie. Z Kardiol 92:283-293
29. Schulte HD, Bircks W, Körfer R, Kuhn H (1981) Surgical aspects of typical subaortic and atypical midventricular hypertrophic obstructive cardiomyopathy (HOCM). Thorac Cardiovasc Surg 29:375-380
30. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Lösse B, Schwartzkopff B (1999) Management of symptomatic hypertrophic obstructive cardiomyopathy. Long term results after surgical therapy. Thorac Cardiovasc Surg 47:213-218
31. Schulte HD, Gramsch-Zabel H, Schwartzkopff R (1995) Hypertrophic obstructive cardiomyopathy (HOCM); surgical management. Schweiz Med Wochenschr 125:1940-1949
32. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 31:252-258
33. Shamim W, Yousufuddin M, Wang D, Henein M, Seggewiss H, Rather M, Coats AJ, Sigwart U (2002) Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med 347:1326-1333
34. Sigwart U (1995) Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 346:211-214
35. Statistisches Bundesamt, 11.koordinierte Bevö lkerungsvorausberechnung, November 2006
36. Veselka J, Duchonova R, Prochazkova S, Palenickova J, Soraija P, Tesar D (2005) Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 95:675-678